Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine for treating ALS and use thereof

A drug and drug delivery technology, applied in the field of biomedicine, to achieve the effect of good application prospects

Inactive Publication Date: 2021-02-23
李启芳
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the important role of oxidative stress in the pathogenesis of ALS, in May 2017, the US FDA approved edaravone, a scavenger for free radicals generated during oxidative stress, for the treatment of mild ALS, not The specific drugs for the treatment of ALS are to improve the neurological symptoms caused by acute cerebral infarction and relieve some symptoms of ALS, but they cannot fundamentally reverse the development of the disease
There is no conclusive evidence for other drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine for treating ALS and use thereof
  • Combined medicine for treating ALS and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] "Ranges" are disclosed herein in terms of lower limits and upper limits. There can be one or more lower bounds, and one or more upper bounds, respectively. A given range is defined by selecting a lower limit and an upper limit. Selected lower and upper limits define the boundaries of a particular range. All ranges that may be defined in this manner are inclusive and combinable, ie, any lower limit may be combined with any upper limit to form a range. For example, ranges of 60-120 and 80-110 are listed for a particular parameter, with the understanding that ranges of 60-110 and 80-120 are contemplated. Additionally, if the minimum range values ​​1 and 2 are listed, and if the maximum range values ​​3, 4, and 5 are listed, the following ranges are all expected: 1-3, 1-4, 1-5, 2- 3, 2-4 and 2-5.

[0028] In the present invention, unless otherwise specified, all the embodiments and preferred embodiments mentioned herein can be combined with each other to form new techni...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a combined medicine for treating ALS. The combined medicine comprises an anti-choline medicine and a sedative medicine which are combined for use. The anti-choline medicine andsedative medicine are used according to a specific ratio, so that a treatment effect can be effectively enhanced. The combined medicine has small side effects or no side effects and has high safety. Meanwhile, the combined medicine can effectively treat ALS and has an effect better than that of single use of the anti-choline medicine scopolamine, indicating that the medicines have a synergistic interaction effect when used in cooperation according to a specific proportion, and the combined medicine has a good clinical application prospect.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to combined drugs, including anticholinergic drugs and sedative drugs, for treating ALS. Background technique [0002] Amyotrophic lateral sclerosis (ALS) is a severe and fatal neurodegenerative disease with unknown etiology, rapid progression after onset, and lack of effective treatment. It is the most common and serious type of motor neuron disease. ALS mainly involves the pyramidal tract, brain stem, and anterior horn motor neurons of the spinal cord. The clinical manifestations are progressive muscle atrophy, weakness, and bulbar palsy, and eventually death due to respiratory failure. [0003] The motor symptoms and signs of ALS upper and lower motor neuron damage are the main manifestations. For example, upper motor neuron involvement can show increased muscle tension, active or hyperactive tendon reflexes, positive pathological signs, and clumsy movements; lower...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P25/00A61P21/00
CPCA61K45/06A61P25/00A61P21/00
Inventor 李启芳
Owner 李启芳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com